Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cellectar, a privately-held radiopharmaceuticals company that designs and develops products to detect, treat and monitor human cancers, has appointed Charles Harwood, Jr, to its board of directors.
Subscribe to our email newsletter
Mr Harwood is a healthcare industry advisor for Avista Capital Partners, a private equity firm. Prior to working with Avista, Mr Harwood was president and CEO of privately-held Focus Diagnostics.
Mr Harwood also serves on the board of directors at BioReliance, a contract research organization specializing in biological safety testing and specialized toxicology, RadPharm, a privately-held contract research organization located in Princeton, New Jersey, and Itero Biopharmaceuticals, a development stage company located in the San Francisco Bay Area.
William Clarke, president and CEO of Cellectar, said: “Charlie brings exceptional financial and transaction expertise to the Cellectar board. His years of experience in the drug development industry will prove beneficial to the company as we advance our radiopharmaceutical products toward clinical testing and commercialization.”